MedTrace Logo

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

NCT06689956 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 212

Last updated 2026-02-19

No results posted yet for this study

Summary

This study evaluates whether isolated tumor cells in the first lymph nodes near the tumor can tell researchers something important about the future of patients with a certain type of endometrial (uterine) cancer.

Conditions

  • FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
  • FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
  • Stage IA1 Endometrial Cancer FIGO 2023
  • Stage IA2 Endometrial Cancer FIGO 2023

Interventions

OTHER

Non-Interventional Study

Non-Interventional Study

Sponsors & Collaborators

Principal Investigators

  • Gretchen E. Glaser, MD · Mayo Clinic in Rochester

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-04
Primary Completion
2029-10-31
Completion
2029-10-31

Countries

  • United States
  • Austria
  • Brazil
  • Canada
  • France
  • Germany
  • Israel
  • Italy
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06689956 on ClinicalTrials.gov